Abstract:AbstractBackgroundAmong the indicated pathogenic factors of Alzheimer’s disease (AD), mitochondrial dysfunction has been recognized as an essential contributor, especially for the late onset AD (LOAD). That this observed dysfunction is the cause or consequences of other AD‐related injuries has been debated, results from both sides are in agreement that the roles of mitochondria in connection with other AD pathologies are convergent. This strongly advocates that targeting mitochondrial dysfunction represents a promising approach to develop more effective AD therapeutics.MethodChemical probes based on a novel lead structure that showed promising neuroprotective activities both in vitro and in vivo AD models were designed and synthesized to identify protein targets. Mouse brain mitochondria were purified from C57BL/6 mice and complex I was further isolated. OXPHOS studies were conducted in purified mitochondria upon treatment with our lead compound. Photo‐affinity labeling studies were conducted upon incubation of chemical probes with complex I. Colocalization was studied using neuronal MC65 cells and chemical probes.ResultOXPHOS studies established that the lead compound only modulated the state 3 respiratory of pyruvate, the complex I substrate, but not succinate, the complex II substrate. Enzymatic studies of ETC also confirmed its selective modulation of complex I. The immunocytochemistry studies in MC65 cells indicated that the designed chemical probe localized to mitochondria. Protein labeling studies confirmed the direct interaction of the chemical probe with mitochondria complex I. Further analysis suggested that our chemical probe binds to the FMN binding site of complex I. Competition studies using the lead compound and NADH supported the selective labeling of complex I sub‐units.ConclusionStudies from in vitro, ex vivo, and in vivo models established that the lead compound selectively modulates the production of mitochondria complex I ROS without interfering with mitochondria membrane potential and bioenergetics, representing a novel mechanism of action. Chemical biology studies employing photo‐affinity labeling probes also confirmed the interaction of the probes with complex I and suggested the FMN binding site as the interaction site. Collectively, the results strongly encourage developing mitochondria complex I ROS modulators based on this novel chemical scaffold as potential AD therapeutics.

An Analog Derived from Phenylpropanoids Ameliorates Alzheimer's Disease-Like Pathology and Protects Mitochondrial Function.

A Newly Synthesized Rhamnoside Derivative Alleviates Alzheimer's Amyloid-β-Induced Oxidative Stress, Mitochondrial Dysfunction, and Cell Senescence Through Upregulating SIRT3.

Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as Multifunctional Agents for the therapy of Alzheimer's Disease.

Oxyphylla A ameliorates cognitive deficits and alleviates neuropathology via the Akt-GSK3β and Nrf2-Keap1-HO-1 pathways in vitro and in vivo murine models of Alzheimer's disease

A Novel Rhamnoside Derivative PL402 Up-Regulates Matrix Metalloproteinase 3/9 to Promote Aβ Degradation and Alleviates Alzheimer’s-like Pathology

Neuronal mitochondria-targeted micelles relieving oxidative stress for delayed progression of Alzheimer's disease.

Reprogramming the neuronal secretory and metabolic machinery using correctors for Alzheimer therapy

The n-terminal 5-MER peptide analogue P165 of amyloid precursor protein exerts protective effects on SH-SY5Y cells and rat hippocampus neuronal synapses.

Small molecule modulation of TrkB and TrkC neurotrophin receptors prevents cholinergic neuron atrophy in an Alzheimer's disease mouse model at an advanced pathological stage

Nanoformulated Alpha-Mangostin Ameliorates Alzheimer's Disease Neuropathology by Elevating LDLR Expression and Accelerating Amyloid-Beta Clearance

Modulation of Mitochondrial Complex I Activity Averts Cognitive Decline in Multiple Animal Models of Familial Alzheimer's Disease

Microenvironment Modulating Nanogels by Shiitake-derived Lentinan and a Reactive Oxygen Species Scavenging Conjugated Polymer for the Treatment of Alzheimer’s Disease

RESTORATION OF AXONAL TRAFFICKING OF MITOCHONDRIA AVERTS COGNITIVE DECLINE IN MOUSE MODELS OF FAMILIAL ALZHEIMER'S DISEASE

Novel Modulators of Mitochondrial Complex I ROS Production As Potential AD Therapeutics

Dipotassium N-stearoyltyrosinate Ameliorated Pathological Injuries in Triple-Transgenic Mouse Model of Alzheimer's Disease

A novel PDHK inhibitor restored cognitive dysfunction and limited neurodegeneration without affecting amyloid pathology in 5xFAD mouse, a model of Alzheimer's disease

A Novel Multifunctional 5,6-Dimethoxy-indanone-chalcone-carbamate Hybrids Alleviates Cognitive Decline in Alzheimer’s Disease by Dual Inhibition of Acetylcholinesterase and Inflammation

20(S)-protopanaxadiol and oleanolic acid ameliorate cognitive deficits in APP/PS1 transgenic mice by enhancing hippocampal neurogenesis

Plasmalogen Improves Memory Function by Regulating Neurogenesis in a Mouse Model of Alzheimer's Diseases.

Cholinergic Neuron Targeting Nanosystem Delivering Hybrid Peptide for Combinatorial Mitochondrial Therapy in Alzheimer?s Disease

DL0410 ameliorates cognitive disorder in SAMP8 mice by promoting mitochondrial dynamics and the NMDAR-CREB-BDNF pathway